Altimmune (ALT) Corporate presentation summary

Strategic focus and mission

• Aims to revolutionize care for serious liver diseases, targeting MASH, AUD, and ALD.

• Pemvidutide, a dual glucagon/GLP-1 agonist, is the lead candidate with a unique 1:1 mechanism.

• Strong patent protection extends into the 2040s, supporting long-term franchise potential.

• Maintains a robust cash position of $519 million, funding operations through key Phase 3 data in 2029.

Clinical pipeline and milestones

• Initiated PERFORMA Phase 3 MASH trial in July 2026 following compelling Phase 2 results.

• Reported strong positive topline data for AUD in July 2026; ALD Phase 2 trial completed enrollment.

• Pemvidutide has received FDA Fast Track and Breakthrough Therapy designations for MASH and AUD.

• Anticipates 52-week Phase 3 MASH data readout in 2029, with global trial enrollment underway.

Market opportunity and disease burden

• MASH, AUD, and ALD represent large, overlapping populations with significant unmet needs.

• By 2030, 10.6M MASH (F2/F3), 12M moderate/severe AUD, and 6M ALD patients projected in the US.

• MASH is a leading cause of liver transplantation and is associated with obesity and diabetes.

• AUD and ALD populations have high comorbidity and lack effective, liver-directed therapies.